The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Parkinson's disease (PD) is the second most common neurodegenerative disease
worldwide, and its treatment remains a big challenge. The pathogenesis of PD may be …

Alpha-synuclein (α-Syn) is a key protein involved in Parkinson's disease (PD) pathology. PD
is characterized by the loss of dopaminergic neuronal cells in the substantia nigra pars …

With the advent of the genetic era in Parkinson's disease (PD) research in 1997, α-synuclein
was identified as an important player in a complex neurodegenerative disease that affects> …

The two main pathological hallmarks of Parkinson's disease are loss of dopamine neurons
in the substantia nigra pars compacta and proteinaceous amyloid fibrils composed mostly of …

The greatest unmet therapeutic need in Parkinson's disease is the development of treatment
that slows the relentless progression of the neurodegenerative process. The concept of …

Over 20 years ago, the synaptic protein α-synuclein was identified as the primary component
of the Lewy bodies (LBs) that are a sine qua non of Parkinson's disease (PD). Since that …

Parkinson disease (PD) treatment options have conventionally focused on dopamine
replacement and provision of symptomatic relief. Current treatments cause undesirable …

Filamentous tau aggregates are hallmark lesions in numerous neurodegenerative diseases,
including Alzheimer's disease (AD). Cell culture and animal studies showed that tau fibrils …

Parkinson's disease (PD) is characterized by the progressive appearance of intraneuronal
Lewy aggregates, which are primarily composed of misfolded α-synuclein (α-syn). The …